

Christos V Rizos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8854416/publications.pdf>

Version: 2024-02-01

24
papers

515
citations

840119

11
h-index

642321

23
g-index

25
all docs

25
docs citations

25
times ranked

1011
citing authors

#	ARTICLE	IF	CITATIONS
1	Metformin and cancer. <i>European Journal of Pharmacology</i> , 2013, 705, 96-108.	1.7	131
2	Antihypertensive drugs and glucose metabolism. <i>World Journal of Cardiology</i> , 2014, 6, 517.	0.5	68
3	The current role of thiazolidinediones in diabetes management. <i>Archives of Toxicology</i> , 2016, 90, 1861-1881.	1.9	54
4	Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: A 24-week, randomized, open-label, prospective study. <i>Clinical Therapeutics</i> , 2010, 32, 492-505.	1.1	43
5	Does Combination Therapy with Statins and Fibrates Prevent Cardiovascular Disease in Diabetic Patients with Atherogenic Mixed Dyslipidemia?. <i>Review of Diabetic Studies</i> , 2013, 10, 171-190.	0.5	31
6	Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 3-12.	1.0	26
7	Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). <i>Atherosclerosis</i> , 2018, 277, 308-313.	0.4	26
8	LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments. <i>International Journal of Cardiology</i> , 2021, 345, 119-124.	0.8	19
9	Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1121-1132.	1.0	18
10	Emerging Fixed-Dose Combination Treatments for Hyperlipidemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 315-322.	1.0	14
11	The effect of combining rosuvastatin with sartans of different peroxisome proliferator receptor- β activating capacity on plasma 8-isoprostane prostaglandin F _{2a} levels. <i>Archives of Medical Science</i> , 2013, 1, 172-176.	0.4	12
12	Reaching low density lipoprotein cholesterol targets. <i>Current Medical Research and Opinion</i> , 2014, 30, 1967-1969.	0.9	12
13	An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). <i>Hormones</i> , 2017, 16, 306-312.	0.9	9
14	The Effect of Rosuvastatin on Low-Density Lipoprotein Subfractions in Patients With Impaired Fasting Glucose. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015, 20, 276-283.	1.0	8
15	Severe hyperkalemia following blood transfusions: Is there a link?. <i>World Journal of Nephrology</i> , 2017, 6, 53.	0.8	8
16	Combining Rosuvastatin With Angiotensin-Receptor Blockers of Different PPAR β -Activating Capacity. <i>Angiology</i> , 2015, 66, 36-42.	0.8	7
17	Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 117-125.	1.5	6
18	Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry. <i>Lipids in Health and Disease</i> , 2020, 19, 114.	1.2	6

#	ARTICLE	IF	CITATIONS
19	Combining Rosuvastatin with Sartans of Different Peroxisome Proliferator-Activated Receptor- α 3 Activating Capacity Is Not Associated with Different Changes in Low-Density Lipoprotein Subfractions and Plasma Lipoprotein-Associated Phospholipase A ₂ . <i>Metabolic Syndrome and Related Disorders</i> , 2011, 9, 217-223.	0.5	5
20	Statin myopathy: navigating the maze. <i>Current Medical Research and Opinion</i> , 2017, 33, 327-329.	0.9	4
21	Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH. <i>Endocrine</i> , 2022, 76, 324-330.	1.1	4
22	Telmisartan: a multifaceted antihypertension drug. <i>Current Medical Research and Opinion</i> , 2016, 32, 1397-1398.	0.9	2
23	Antihypertensive drug therapy in patients with African ancestry. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1061-1064.	0.9	1
24	Prevalence of Non-coronary Heart Disease in Patients with Familial Hypercholesterolemia: An Analysis from the HELLAS-FH. <i>Current Pharmaceutical Design</i> , 2021, 27, 2537-2544.	0.9	1